Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Drug Regulators Issue New Rules To Increase Safety Standards Of Vaccines

This article was originally published in PharmAsia News

Executive Summary

BEIJING - In the wake of a series of vaccine scandals across China during the past year, triggering sometimes fatal adverse events, China's State FDA is strengthening rules governing the manufacturing, distribution and inspection of vaccines nationwide

You may also be interested in...



Are China’s Vaccines Ready For The World?

With WHO approval in hand, China’s vaccine industry looks to take the next step into global markets.

What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)

SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus

What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)

SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus

Related Content

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel